Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: An analysis from the randomized transform study

Medicine and Dentistry

• Kidney Graft 100%
• Calcineurin Inhibitor 100%
• Everolimus 100%
• Mycophenolic Acid 60%
• BK Virus 40%
• Virus Infection 30%
• Adverse Event 20%
• Cytomegalovirus Infection 20%
• Hyperlipidemia 10%
• Thrombocytopenia 10%
• Cytomegalovirus 10%
• Nausea 10%
• Nephropathy 10%
• Proteinuria 10%
• Interstitial Lung Disease 10%
• Diarrhea 10%
• Wound Healing 10%
• Stomatitis 10%
• Leukopenia 10%
• Mouth Ulcer 10%
• Peripheral Edema 10%
• Healing Impairment 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Calcineurin Inhibitor 100%
• Everolimus 100%
• Mycophenolic Acid 60%
• BK Virus 40%
• Virus Infection 30%
• Adverse Event 20%
• Cytomegalovirus Infection 20%
• Hyperlipidemia 10%
• Diarrhea 10%
• Syndrome 10%
• Kidney Disease 10%
• Proteinuria 10%
• Nausea 10%
• Cytomegalovirus 10%
• Wound Healing 10%
• Thrombocytopenia 10%
• Leukopenia 10%
• Interstitial Lung Disease 10%
• Mouth Ulcer 10%
• Peripheral Edema 10%
• Stomatitis 10%
• Healing Impairment 10%

Keyphrases

• R-groups 10%